Liquid Biopsy MonitORing Of CholangioCarcinOma for Treatment Response and Prognostic Outcomes (MOROCCO)

Enrolling by invitation

Conditions studied: Cholangiocarcinoma

In brief

This study explores the potential value of a new blood test approach to detect measurable residual disease or early recurrence/progression in patients with cholangiocarcinoma.

Key facts

Study ID

NCT06474091

Run by

Mayo Clinic

People needed

100

Starts

2024-05-08

Expected to finish

2029-05-08

Last updated by the study team

2026-03-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient has a suspected or clinical diagnosis of cholangiocarcinoma and under evaluation for surgical intervention with intent to cure
• Age ≥ 18 years

You may not qualify if…

• Patient has metastatic disease involving other organs (excluding lymph node)
• Patent has known primary cancer outside of the bile ducts within the last 3 years prior to blood collection (not including basal cell or squamous cell skin cancers, indolent cancer not requiring treatment within 3 years i.e. kidney, prostate or thyroid being observed)
• Patient has had surgery to remove current target pathology completely or partially
• Patient has undergone any prior radiation therapy to target lesion prior to blood collection
• Patient has received chemotherapy class drugs in the 3 years prior to blood collection
• Patient has had any transplants prior to blood collection
• Current target pathology is a recurrence

Where it is running

• Mayo Clinic in Rochester — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.